Skip NavigationSkip to Content
Return Return to Search Results

MTHFR genotype and colorectal adenoma recurrence: Data from a double-blind placebo-controlled clinical trial

  1. Author:
    Levine, A. J.
    Wallace, K.
    Tsang, S.
    Haile, R. W.
    Saibil, F.
    Ahnen, D.
    Cole, B. F.
    Barry, E. L.
    Munroe, D. J.
    Ali, I. U.
    Uel, P.
    Baron, J. A.

  2. Author Address

    Levine, A. Joan, Haile, Robert W.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Wallace, Kristin, Barry, Elizabeth L.; Baron, John A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA. [Baron, John A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA. [Ali, Iqbal U.] SAIC Frederick Inc, NCI, Lab Mol Technol, Adv Technol Program, Frederick, MD USA. [Saibil, Fred] Univ Toronto, Dept Med, Toronto, ON, Canada. [Ahnen, Dennis] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. [Ueland, Per] Univ Bergen, Pharmacol Sect, Inst Med, Bergen, Norway. [Ueland, Per] Haukeland Hosp, N-5021 Bergen, Norway. [Cole, Bernard F.] Univ Vermont, Dept Math & Stat, Coll Engn & Math Sci, Burlington, VT 05405 USA.
    1. Year: 2008
  2. Journal: Cancer Epidemiology Biomarkers & Prevention
    1. 17
    2. 9
    3. Pages: 2409-2415
  4. Type of Article: Article
  1. Abstract:

    Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism. We assessed the association between two common MTHFR variants, 677C > T and 1298A > C, and adenoma recurrence in the context of a randomized double-blind clinical trial of aspirin use and folate supplementation. We used generalized linear regression to estimate risk ratios and 95% confidence intervals (95% CI) for recurrence, adjusting for age, sex, clinical center, follow-up time, and treatment status. Neither MTHFR polymorphism was associated with overall or advanced adenoma recurrence. Compared with those with two wild-type alleles, the relative risk for advanced adenoma was 0.75 (95% CI, 0.36-1.55) for the MTHFR 677 TT genotype and 1.16 (95% CI, 0.58-2.33) for the MTHFR 1298 CC genotype. The effect of folate supplementation on recurrence risk did not differ by genotype. Our findings indicate that the MTHFR genotype does not change adenoma risk in a manner similar to its effect on colorectal cancer, and does not modify the effect of folate supplementation on metachronous adenoma risk.

    See More

  1. Keywords:

External Sources

  1. PMID: 18768511

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel